论文部分内容阅读
1993～1996年应用经皮肝动脉药物灌注栓塞（HACE）与肝瘤坏死因子联合治疗中晚期肝癌35例，与同期单独应用HACE治疗的23例作初步比较，发现联合治疗组和对照组的肿瘤缩小率分别为56．2％和51，4％，差异无显著意义（P＞0．05）。联合治疗组和对照组平均生存时间分别为18月和14月，联合治疗组较对照组高，但差异无显著意义（P>0．05）。免疫功能联合治疗组下降不明显（P>O．05），而对照组明显下降（P>O．05）。作者认为中晚期肝癌在HACE治疗中应用TNF作为辅助治疗手段，对于提高患者免疫功能，延长生存期具有一定作用，值得进一步观察。
From 1993 to 1996, 35 cases of advanced hepatocellular carcinoma were treated with percutaneous transhepatic artery perfusion embolization (HACE) and hepatic necrosis factor, and compared with 23 cases treated with HACE alone during the same period. Tumors of the combination therapy group and the control group were found. The reduction rates were 56.2% and 51.4%, respectively, with no significant difference (P>0.05). The average survival time of the combined treatment group and the control group was 18 months and 14 months, respectively, and the combination treatment group was higher than the control group, but the difference was not significant (P>0.05). There was no significant decrease in the immune function combination treatment group (P>O.05), but it was significantly decreased in the control group (P>O.05). The authors believe that the use of TNF as an adjunct in the treatment of advanced hepatocellular carcinoma in HACE has a certain effect on improving the patient’s immune function and prolonging survival, and it is worthy of further observation.